Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
426 Views
Emedinexus 21 November 2024
The European Medicines Agency (EMA) has granted approval for dasiglucagon in 2024, providing a new therapeutic option for the treatment of severe hypoglycemia in diabetes patients. Dasiglucagon, a novel rescue therapy, is formulated to rapidly elevate blood glucose levels during severe hypoglycemic episodes, which can lead to confusion, seizures, unconsciousness, and, in extreme cases, death if not treated promptly. This approval marks a significant advancement in emergency management for diabetic patients, offering a fast-acting and effective solution to prevent life-threatening complications associated with dangerously low blood sugar levels.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}..
Could Semaglutide be a Game Changer in Managing Obesity and Osteoarthr.....
Benefits of levothyroxine in patients with subclinical hypothyroidism .....
Sedentary Behavior and Cardiovascular Risk: How Much Sitting is Too Mu.....
Perimenopause and Its Challenges..
Today is World Diabetes Day: “Diabetes and Well-beingâ€..
{{Article_Title}}..
Doctors' Body Demands Dissolution of West Bengal Medical Council amid Corruption Allegations..
Indian Chest Society Urges NMC to Reinstate Respiratory Medicine in MBBS Curriculum..
Centre to Launch First PPP Specialty Hospitals in Odishas Underserved Districts..
Inquiry Ordered Into Alleged Medical Negligence at Muzaffarpur Hospital..
NABH and RSSDI Join Forces to Improve Diabetes Care in India..